Cargando…
Cross-validation of comorbidity items in two national databases in a sample of patients with end-stage kidney disease
BACKGROUND: The use of national medico-administrative databases for epidemiological studies has increased in the last decades. In France, the Healthcare Expenditures and Conditions Mapping (HECM) algorithm has been developed to analyse and monitor the morbidity and economic burden of 58 diseases. We...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10594771/ https://www.ncbi.nlm.nih.gov/pubmed/37872574 http://dx.doi.org/10.1186/s12913-023-10145-y |
_version_ | 1785124720424779776 |
---|---|
author | Vanorio-Vega, Isabella Constantinou, Panayotis Hami, Assia Cellarier, Eric Rachas, Antoine Tuppin, Philippe Couchoud, Cécile |
author_facet | Vanorio-Vega, Isabella Constantinou, Panayotis Hami, Assia Cellarier, Eric Rachas, Antoine Tuppin, Philippe Couchoud, Cécile |
author_sort | Vanorio-Vega, Isabella |
collection | PubMed |
description | BACKGROUND: The use of national medico-administrative databases for epidemiological studies has increased in the last decades. In France, the Healthcare Expenditures and Conditions Mapping (HECM) algorithm has been developed to analyse and monitor the morbidity and economic burden of 58 diseases. We aimed to assess the performance of the HECM in identifying different conditions in patients with end-stage kidney disease (ESKD) using data from the REIN registry (the French National Registry for patients with ESKD). METHODS: We included all patients over 18 years of age who started renal replacement therapy in France in 2018. Five conditions with a similar definition in both databases were included (ESKD, diabetes, human immunodeficiency virus [HIV], coronary insufficiency, and cancer). The performance of each SNDS algorithm was assessed using sensitivity, specificity, positive predictive values (PPVs), negative predictive values (NPVs), and Cohen’s kappa coefficient. RESULTS: In total 5,971 patients were included. Among them, 81% were identified as having ESKD in both databases. Diabetes was the condition with the best performance, with a sensitivity, specificity, PPV, NPV, and Kappa coefficient all over 80%. Cancer had the lowest level of agreement with a Kappa coefficient of 51% and a high specificity and high NPV (94% and 95%). The conditions for which the definition in the HECM included disease-specific medications performed better in our study. CONCLUSION: The HECM showed good to very good concordance with the REIN database information overall, with the exception of cancer. Further validation of the HECM tool in other populations should be performed. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12913-023-10145-y. |
format | Online Article Text |
id | pubmed-10594771 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-105947712023-10-25 Cross-validation of comorbidity items in two national databases in a sample of patients with end-stage kidney disease Vanorio-Vega, Isabella Constantinou, Panayotis Hami, Assia Cellarier, Eric Rachas, Antoine Tuppin, Philippe Couchoud, Cécile BMC Health Serv Res Research BACKGROUND: The use of national medico-administrative databases for epidemiological studies has increased in the last decades. In France, the Healthcare Expenditures and Conditions Mapping (HECM) algorithm has been developed to analyse and monitor the morbidity and economic burden of 58 diseases. We aimed to assess the performance of the HECM in identifying different conditions in patients with end-stage kidney disease (ESKD) using data from the REIN registry (the French National Registry for patients with ESKD). METHODS: We included all patients over 18 years of age who started renal replacement therapy in France in 2018. Five conditions with a similar definition in both databases were included (ESKD, diabetes, human immunodeficiency virus [HIV], coronary insufficiency, and cancer). The performance of each SNDS algorithm was assessed using sensitivity, specificity, positive predictive values (PPVs), negative predictive values (NPVs), and Cohen’s kappa coefficient. RESULTS: In total 5,971 patients were included. Among them, 81% were identified as having ESKD in both databases. Diabetes was the condition with the best performance, with a sensitivity, specificity, PPV, NPV, and Kappa coefficient all over 80%. Cancer had the lowest level of agreement with a Kappa coefficient of 51% and a high specificity and high NPV (94% and 95%). The conditions for which the definition in the HECM included disease-specific medications performed better in our study. CONCLUSION: The HECM showed good to very good concordance with the REIN database information overall, with the exception of cancer. Further validation of the HECM tool in other populations should be performed. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12913-023-10145-y. BioMed Central 2023-10-24 /pmc/articles/PMC10594771/ /pubmed/37872574 http://dx.doi.org/10.1186/s12913-023-10145-y Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Vanorio-Vega, Isabella Constantinou, Panayotis Hami, Assia Cellarier, Eric Rachas, Antoine Tuppin, Philippe Couchoud, Cécile Cross-validation of comorbidity items in two national databases in a sample of patients with end-stage kidney disease |
title | Cross-validation of comorbidity items in two national databases in a sample of patients with end-stage kidney disease |
title_full | Cross-validation of comorbidity items in two national databases in a sample of patients with end-stage kidney disease |
title_fullStr | Cross-validation of comorbidity items in two national databases in a sample of patients with end-stage kidney disease |
title_full_unstemmed | Cross-validation of comorbidity items in two national databases in a sample of patients with end-stage kidney disease |
title_short | Cross-validation of comorbidity items in two national databases in a sample of patients with end-stage kidney disease |
title_sort | cross-validation of comorbidity items in two national databases in a sample of patients with end-stage kidney disease |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10594771/ https://www.ncbi.nlm.nih.gov/pubmed/37872574 http://dx.doi.org/10.1186/s12913-023-10145-y |
work_keys_str_mv | AT vanoriovegaisabella crossvalidationofcomorbidityitemsintwonationaldatabasesinasampleofpatientswithendstagekidneydisease AT constantinoupanayotis crossvalidationofcomorbidityitemsintwonationaldatabasesinasampleofpatientswithendstagekidneydisease AT hamiassia crossvalidationofcomorbidityitemsintwonationaldatabasesinasampleofpatientswithendstagekidneydisease AT cellariereric crossvalidationofcomorbidityitemsintwonationaldatabasesinasampleofpatientswithendstagekidneydisease AT rachasantoine crossvalidationofcomorbidityitemsintwonationaldatabasesinasampleofpatientswithendstagekidneydisease AT tuppinphilippe crossvalidationofcomorbidityitemsintwonationaldatabasesinasampleofpatientswithendstagekidneydisease AT couchoudcecile crossvalidationofcomorbidityitemsintwonationaldatabasesinasampleofpatientswithendstagekidneydisease |